|

Cemiplimab-Rwlc Clinical Trials

3 actively recruiting trials across 3 locations

▲ +1 trial since August 2026

Also known as: Libtayo

Pipeline

Phase 1: 1Phase 2: 2

Top Sponsors

  • Wake Forest University Health Sciences1
  • H. Lee Moffitt Cancer Center and Research Institute1
  • Georgetown University1

Indications

  • Cancer3
  • Lung Cancer2
  • Performance Status1
  • Non-small Cell Lung Cancer Stage III1
  • Nonsmall-cell Lung Cancer1

Washington D.C., District of Columbia1 trial

Neoadjuvant Chemo-Immunotherapy and Surgical Resection in Locally Advanced Non-small Cell Lung Cancer With N3 Lymph Node or Other High Risk Features

Lombardi Comprehensive Cancer Center, Georgetown University

Phase 2

Tampa, Florida1 trial

Neoadjuvant Cemiplimab in Newly Diagnosed or Recurrent Stage I-II Merkel Cell Carcinoma and Locoregionally Advanced Cutaneous Squamous Cell Carcinoma

Moffitt Cancer Center

Phase 1

Winston-Salem, North Carolina1 trial

Pilot Study of Performance Status 2 vs. Performance Status 0-1 Non-small Cell Lung Cancer Patients Treated With Chemo/Immunotherapy

Wake Forest Baptist Comprehensive Cancer Center

Phase 2

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.